Related Experiment Video
Updated: Aug 17, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
The safety of 7-valent pneumococcal conjugate vaccine
1Department of Pediatric Infectious Disease, Southwestern Medical Center, University of Texas, Dallas, Texas 75390-9063, USA. faryal.ghaffar@utsouthwestern.edu
Insights
The heptavalent pneumococcal conjugate vaccine (PCV-7) is safe and effective for young children, including those with HIV or sickle cell disease. Ongoing surveillance is crucial to ensure PCV-7 remains optimal for preventing invasive pneumococcal disease.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Bacteriology
Background:
- Streptococcus pneumoniae is a leading bacterial pathogen in young children.
- Several pneumococcal conjugate vaccines are in development or licensed.
- The heptavalent pneumococcal conjugate vaccine (PCV-7) is currently the only approved vaccine for invasive pneumococcal disease in children under two.
Purpose of the Study:
- To review the safety and efficacy of the PCV-7 vaccine.
- To assess the vaccine's performance in specific pediatric populations.
- To emphasize the importance of ongoing surveillance for serotype distribution.
Main Methods:
- Review of existing safety and clinical trial data for PCV-7.
- Analysis of surveillance data on invasive pneumococcal disease serotypes.
- Evaluation of PCV-7 in vulnerable pediatric groups.
Main Results:
- PCV-7 demonstrates acceptable safety when administered alone or with other vaccines.
- The vaccine is safe and immunogenic in infants with HIV and sickle cell disease.
- Surveillance data is essential for confirming PCV-7's continued effectiveness.
Conclusions:
- PCV-7 is a safe and effective vaccine for preventing invasive pneumococcal disease in young children.
- The vaccine's safety profile extends to infants with co-existing conditions like HIV and sickle cell disease.
- Continuous monitoring of pneumococcal serotypes is vital for maintaining vaccine efficacy and public health strategies.
Abstract:
Streptococcus pneumoniae is one of the most important bacterial pathogens of young children. Currently, there are several conjugate vaccines against S. pneumoniae in various stages of laboratory development, clinical evaluation or currently licensed. Heptavalent pneumococcal conjugate vaccine (Wyeth Lederle; PCV-7) is the only currently approved pneumococcal conjugate vaccine indicated against invasive pneumococcal disease for children younger than two years of age. Safety studies have shown that the PCV-7 is acceptably safe when administered alone, simultaneously with other childhood vaccines or in combination with Haemophilus influenzae type b conjugate vaccines. In addition, PCV-7 vaccine was generally safe and immunogenic among infants infected with HIV and those with sickle cell disease. Surveillance studies to monitor the serotype distribution in invasive pneumococcal disease is important to determine that PCV-7 continues to be the optimal vaccination for prevention of pneumococcal invasive disease.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Streptococcal Pharyngitis
Vaccinations
Vaccines
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Cryptococcal Meningitis
Teratogenicity